RxDoctor Payments Data

Maykel Trotter, MD

Internal Medicine · Miami Beach, FLNPI 1801134465

Payments from drug & device makers

$29,451in general payments, 2019–2025

Across 883 payments — averaging $33.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$13K
  • Novo Nordisk$2K
  • Lilly USA, LLC$2K
  • AbbVie$1K
  • Boehringer Ingelheim$1K
  • Amgen$855
  • plus $10K from 54 others

What the payments were for

  • Speaking & faculty fees$9,92034%
  • Travel & lodging$6362%
  • Food & beverage$18,80664%
  • Education$890%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca88$12,570
Novo Nordisk105$2,302
Lilly USA, LLC95$1,550
AbbVie(2 entities)73$1,393
Boehringer Ingelheim48$1,213
Amgen46$855
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC40$727
Pfizer31$686
Bayer22$674
Kowa Pharmaceuticals America, Inc.28$599
Boston Scientific7$576
Johnson & Johnson23$443
Sumitomo Pharma America, Inc.18$422
Novartis29$412
Eisai Inc.16$364
Amarin Pharma, Inc.19$360
Sanofi-aventis U.S. LLC17$329
Takeda Pharmaceuticals U.S.A., Inc.16$318
GSK19$302
Otsuka America Pharmaceutical, Inc.10$301
Astellas Pharma US Inc12$283
Exact Sciences11$263
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)11$260
Lexicon Pharmaceuticals, Inc.4$208
Merck10$161
Bausch Health US, LLC9$158
Mylan Specialty L.p.6$147
Edwards Lifesciences1$134
Idorsia Pharmaceuticals US Inc7$128
Esperion Therapeutics, Inc.5$104
Abbott5$104
Madrigal Pharmaceuticals2$85
Lundbeck LLC3$80
Azurity Pharmaceuticals, Inc.3$70
Heartflow, Inc.3$68
Redhill Biopharma Inc.4$65
Radius Health, Inc.5$60
Axonics, Inc.1$56
Biohaven Pharmaceutical Holding Company Ltd.2$51
IBSA Pharma Inc.3$50
Ironwood Pharmaceuticals, Inc2$44
E.r. Squibb & Sons, L.L.C.2$39
Vivus LLC2$38
Biohaven Pharmaceuticals, Inc.1$36
Nevro Corp.1$34
Viiv Healthcare Company1$33
Viatris Specialty LLC1$31
Nabriva Therapeutics, PLC2$31
Gilead2$31
Currax Pharmaceuticals LLC2$28
Travere Therapeutics, Inc.1$23
Portola Pharmaceuticals, LLC1$22
Dexcom, Inc.1$22
Sunovion Pharmaceuticals Inc.1$19
Phadia US Inc.1$17
Amneal Pharmaceuticals LLC1$17
Arbor Pharmaceuticals, Inc.1$15
Duchesnay USA Incorporated1$15
Nalpropion Pharmaceuticals LLC1$14
Medicure Pharma Inc.1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$29,451 in reported general payments places this provider in the 95th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$40,718
Medicare patients
114
Services billed
412

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide57$72,064
JardianceEmpagliflozin42$57,656
OzempicSemaglutide48$49,187
EliquisApixaban34$32,472
TrulicityDulaglutide30$27,310
LinzessLinaclotide18$23,540
EntrestoSacubitril/Valsartan32$23,059
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$19,135
GemtesaVibegron32$17,965
VascepaIcosapent Ethyl33$17,300
RexultiBrexpiprazole11$15,166
Repatha SureclickEvolocumab17$10,623
LivaloPitavastatin Calcium17$9,649
Testosterone21$1,769
Rosuvastatin Calcium76$1,403

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$1,550$99,37487 claims
Boehringer IngelheimJardiance$1,213$57,65642 claims
Novo NordiskOzempic$2,302$49,18748 claims
PfizerEliquis$686$32,47234 claims
AbbVieLinzess, Synthroid$1,393$24,74632 claims
NovartisEntresto$412$23,05932 claims
GSKTrelegy Ellipta$302$19,13515 claims
Sumitomo Pharma America, Inc.Gemtesa$422$17,96532 claims
Otsuka America Pharmaceutical, Inc.Rexulti$301$15,16611 claims
Kowa Pharmaceuticals America, Inc.Livalo$599$9,64917 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$17$56646 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Miami Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →